Oncoshot Works With Novartis To Reform Clinical Trials Management  

Oncoshot has established a strategic partnership with Novartis to leverage its Project EISE platform which has the potential to enable more patients to access clinical trials in Singapore. EISE (pronounced as ‘easy’), an acronym for ‘Enhanced Clinical Trial Initiation, Screening and Enrolment,’ is a nationwide collaborative effort that connects cancer patients through an integrated, state-of-the-art care system. 

 Project EISE provides real-time cancer population insights, enabling Novartis to accelerate its clinical trial site selection process and establish more trial sites in Singapore. Oncoshot’s proprietary clinical trial matching technology provides a trial-to-patient matching and analytics capability for trial sponsors, building a robust advanced cancer ecosystem within Southeast Asia.     

Oncoshot continually strives to build a trusted and data-driven clinical trials ecosystem and is always on the lookout to support trial sites within the region. In the short term, its efforts focus on supporting Novartis’ interest in Singapore. “Novartis is amongst the global oncology leaders bringing highly innovative therapies and trials to APAC,” says Dr Huren Sivaraj, CEO and Co-Founder of Oncoshot. “We look forward to supporting Novartis with real-time population insights from Singapore and aim to bring more innovative Novartis studies to our partner cancer trial sites and support access to therapies for cancer patients in these countries.” 

This partnership will improve the visibility of hospitals in Singapore by going beyond typical standard requirements of experience, investigator interest, and site capabilities by facilitating sharing of insights on living matching patient cohorts, thus, lowering the risk of delay in screening and enrolment. Furthermore, cancer patients in Singapore may benefit from access to more trials resulting from the high-quality interaction between Novartis and trial sites based on matching population insights.

Within the region, Novartis conducts the largest number of cancer studies and works closely with local healthcare systems that provide swift and dependable point-to-point clinical research support for quality studies.   

“Our partnership with Oncoshot allows Novartis to use digital technology for rapid site selection, increasing the rate of screening and enrolment across the different clinical trials. At Novartis, clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. With Oncoshot’s seamless digital platform, we aim to bring transformative medicines to patients faster,” said Atul Chaudhari, Novartis' country monitoring head for Singapore and Malaysia. 

About Oncoshot  

Oncoshot was founded in 2018 by Medical Oncologist Dr Huren Sivaraj and Data Science Engineer Ruslan Enikeev. As a health insights exchange platform, Oncoshot leverages its proprietary clinical trial matching artificial intelligence technology to address the inefficiencies of cancer clinical trials. The platform serves as a bridge between leading regional healthcare institutions and contract research organisations and global biotechnology and pharmaceutical companies to facilitate data-driven cancer clinical trials while accelerating enrolment into actively recruiting ones. Learn more at https://www.oncoshot.com/.  

About Novartis  

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.